Proptosis as initial manifestation of Burkitt's lymphoma with orbital involvement. / Proptosis como manifestación inicial de linfoma de Burkitt con afectación orbitaria.

CASE PRESENTATION: A 35-year-old woman without any known systemic disorder presented with a complaint of painful and rapidly increasing proptosis in her right eye. Based on the clinical, radiological, analytical and ophthalmological assessments, the diagnosis made was Burkitt's lymphoma in acquired immunodeficiency syndrome. CONCLUSION: Proptosis can be an unusual way of presenting with Burkitt's lymphoma associated with acquired immunodeficiency. This differential diagnosis is important because confirmation leads to a change in the vital prognosis of the patient.

Subfoveal choroidal thickness in eyes with diabetic macular oedema using swept source optical coherence tomography. / Grosor coroideo subfoveal medido con tomografía de coherencia óptica swept source en ojos con edema macular diabético.

PURPOSE: To compare subfoveal choroidal thickness (GCSF) in patients with diabetic macular oedema (DMO) and healthy subjects using swept source optical coherence tomography (SS-OCT). METHOD: Cross-sectional study including 50 eyes of 36 patients with DMO, and 47 eyes of 34 patients as a control group. GCSF was measured in both groups, analysing between the eyes with DMO according to the type of oedema (predominantly cystic or diffuse). RESULTS: The study groups were homogeneous in terms of mean age (63.4 years for DMO and 62.65 years for controls; P=.36) and the mean axial length (23.21mm for DME and 23.53mm for controls; P=.06). A statistically significant reduction in the eye with DME GCSF compared to controls (P=.041, 222.9 vs. 192.82 µm) was observed. No statistically significant differences were observed in the eyes with DMO with a predominantly cystic pattern and diffuse oedema (P=.13, 178.68 vs. 205.7 µm). CONCLUSION: The GCSF in patients with DMO could be reduced. Future studies are needed to confirm these preliminary results.

Alternative treatment for retinoblastoma: Intra-arterial chemotherapy with melphalan.

CASE REPORT: A 10-month old infant was referred for the study of a leukocoria of the left eye of one month onset. On examination, a retinoblastoma occupying the macular area was detected. Treatment with intra-arterial chemotherapy (melphalan 6 mg) was performed, with no further intervention required for disease control. DISCUSSION: Melphalan is an effective chemotherapeutic agent. However, its use is limited by the systemic toxicity that may occur. Intra-arterial chemotherapy allows the selective release of melphalan into the ophthalmic artery, thus limiting its systemic toxicity. This combination of efficiency, safety and accuracy makes it an attractive therapeutic alternative for the management of retinoblastoma.